Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Shanghai Pharmaceuticals Holding Co., Ltd
Eli Lilly and Company
St. Jude Children's Research Hospital
Gustave Roussy, Cancer Campus, Grand Paris
St. Jude Children's Research Hospital